Much anticipated knockoff versions of costly biotech medicines are facing delays and obstacles that could cost patients and health systems billions in missed savings.
Several high-profile projects to create so-called biosimilar drugs have faltered in recent months. Merck & Co. dissolved a dedicated biosimilar unit last year and in December retreated from a plan to copy arthritis treatment Enbrel after maker Amgen Inc. gained a new patent. Last fall, Samsung Electronics Co.'s biosimilar unit suspended trials for a version of the cancer drug Rituxan, and generic-drug maker Teva Pharmaceutical Industries Ltd. halted its own Rituxan push.
Read the full story: http://on.wsj.com/XCgjT8
Source: The Wall Street Journal
What We’re Reading: Child RSV Shot Disparities; Hospital Transparency Compliance; Abortion Pill Bans
February 6th 2023A pediatric shot for respiratory syncytial virus (RSV) may not be covered as a free routine vaccine; hospitals fail to comply with payment transparency rules; the fate of abortion pills is in the hands of conservative judges
Read More
The government is allowing Medicare Advantage (MA) plans to delay returning hundreds of millions of dollars or more in government overpayments; a proposed new extension of the Affordable Care Act (ACA) might make birth control coverage more accessible for certain private insurance plans; a study found that students lost around 33% of their school year because of the pandemic’s educational barriers and are struggling to regain that lost time.
Read More
High-Deductible Health Plans and Their Potential Impact on the US Drug Epidemic
October 13th 2022On this episode of Managed Care Cast, we speak with Matthew D. Eisenberg, PhD, lead author of a study published in the October issue of The American Journal of Managed Care® that investigated the use of high-deductible health plans and their impact on substance use disorder care and spending.
Listen
IRA Insulin Cap Could Have Saved Medicare Beneficiaries Millions in 2020
January 30th 2023An HHS report said that if the Inflation Reduction Act (IRA) had been implemented in 2020, Medicare Part D beneficiaries could have saved a total of $734 million, averaging out to about $500 per member.
Read More
2 Clarke Drive
Cranbury, NJ 08512